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Abstract
Background: Metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa is a significant pathogen in burn patients.
Objectives: The aim of this study was to determine the prevalence of carbapenem-resistant P. aeruginosa isolates, including those
resistant to imipenemase (IMP), in a burn unit in Isfahan, Iran.
Patients and Methods: One hundred and fifty P. aeruginosa isolates from burn patients were tested for antibiotic susceptibility by
the disc diffusion method in accordance with CLSI guidelines. Production of MBL was identified with the EDTA disk method. DNA
was purified from the MBL-positive isolates, and detection of the blaIMP gene was performed with PCR.
Results: Fifty-seven out of 150 (38%) isolates were multi-drug resistant (MDR), and 93 (62%) were extensively-drug resistant (XDR).
Among all isolates, the resistance rate to ciprofloxacin, tobramycin, imipenem, meropenem, amikacin, ceftazidime, and cefepime
was higher than 90%, while the resistance rates to piperacillin/tazobactam and aztreonam were 70.7% and 86%, respectively. Colistin
and polymyxin B remained the most effective studied antibiotics. All of the imipenem-resistant P. aeruginosa isolates were MBL-
positive, and 107 out of 144 (74.3%) of the MBL isolates were positive for the blaIMP gene.
Conclusions: The results of this study show that the rate of P. aeruginosa-caused burn wound infections was very high, and many of
the isolates were resistant to three or more classes of antimicrobials. Such extensive resistance to antimicrobial classes is important
because few treatment options remain for patients with burn wound infections. blaIMP-producing P. aeruginosa isolates are a rising
threat in burn-care units, and should be controlled by conducting infection-control assessments.
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1. Background
A burn is described as a traumatic injury to the skin
or other organic tissue, mainly caused by thermal or other
acute exposures. Pseudomonas aeruginosa skin infections
in burn injuries carry a very high mortality rate in burn
units, even with aggressive antibiotic therapy (1). Noso-
comial infections are widespread in burn patients be-
cause of the characteristic aspects of the disease, changes
in the specific and nonspecific components of the im-
mune system, extended hospitalization, and various inva-
sive diagnostic and therapeutic procedures (2-4). Emerg-
ing multidrug-resistant (MDR) strains of P. aeruginosahave
recently caused an unexpected rise in burn wound infec-
tions, sepsis, and associated deaths worldwide (5). Micro-
bial factors, such as type, virulence, and bacterial count (>
105 organisms per gram of tissue) increase the risk of an in-
vasive wound infection. Prolonged use of antibiotics, fre-
quently in combination, has led to the selection of MDR
P. aeruginosa strains. These may cause infections that are
very difficult to treat, as there are few antimicrobial agents
available to eradicate them. Even resistance to carbapen-
ems in burn patients can be considerable.
The risk factors for acquisition of imipenem-resistant
P. aeruginosa include carbapenem use, broad-spectrum an-
tibiotic use, extended length of hospitalization, the pres-
ence of imipenem-resistant P. aeruginosa in the unit, and
the previous presence of imipenem-sensitive P. aeruginosa
in the patient (6). For empiric therapy prior to the acces-
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sibility of susceptibility testing results in burn patients
with serious P. aeruginosa wound infections, a combina-
tion of two antibiotics is suggested because of the high or-
ganism load and the chance of infection with, or develop-
ment of, resistant organisms. Possible regimens include
aztreonam, ciprofloxacin, ceftazidime, cefepime, or an an-
tipseudomonal carbapenem plus an aminoglycoside. Col-
istin has been gradually increasingly used in the manage-
ment of severe infections when no other choices are avail-
able. Consideration of P. aeruginosa in burn patients is im-
portant because it causes severe hospital-acquired infec-
tions, is often antibiotic-resistant (thus complicating the
choice of therapy), and is associated with a high mortality
rate.
2. Objectives
The aim of this study was to determine the prevalence
of carbapenem-resistant P. aeruginosa isolates, including
those resistant to imipenemase (IMP), in a burn unit in Is-
fahan, Iran.
3. Patients and Methods
This descriptive study was conducted at the Imam
Mousa Kazem Burns Hospital in Isfahan, Iran. The data
were obtained from September 2013 to August 2014. A ques-
tionnaire was completed to collect the patients’ data. Sam-
ples from the burn wounds were collected from all pa-
tients and were cultured on sheep blood agar, MacConkey,
and chocolate agar, and incubated for 24 - 48 hours at
37°C. The isolates were confirmed to the species level by
gram staining, catalase and oxidase testing, O/F (oxida-
tion fermentation), pyocyanin pigment production, and
growth at 42°C. The API 20E/NE (bioMerieux, France) was
used. Antimicrobial susceptibility was determined by the
disk diffusion method according to the guidelines of the
clinical laboratory standards institute (CLSI) (7). The fol-
lowing antibiotic disks (Mast Group Ltd., Merseyside, UK)
were used for susceptibility testing: imipenem (10 µg),
meropenem (30 µg), aztreonam (10 µg), cefepime (30 µg),
ceftazidime (30 µg), amikacin (30 µg), tobramycin (30
µg), ciprofloxacin (30 µg), piperacillin/tazobactam (100
µg), colistin (30 µg), and polymyxin B (300 units). The
quality control of antibiotic susceptibility was determined
by P. aeruginosa ATCC27853. The isolates were classified
as MDR if they were resistant to more than three classes
of antimicrobial drugs. Extensively-drug resistant (XDR)
was defined as bacterial isolates susceptible to only one
or two categories. Pan-drug resistant (PDR) was defined
as non-susceptibility to all agents in all of the antimicro-
bial categories. Imipenem-resistant isolates were screened
for MBL production. The double-disk synergy test (DDST)
was performed for identification of MBLs by imipenem
(10 µg) alone and in combination with EDTA (750 µg/disk)
(ROSCO, Denmark). An increased zone diameter of ≥ 7
mm around the imipenem plus EDTA disk compared to
that of the imipenem disk alone was considered posi-
tive for MBL production. DNA templates were prepared
by the boiling method, and the polymerase chain reac-
tion (PCR) amplification for blaIMP was performed with the
primers MIP-F (5’-GAAGGCGTTTATGTTCATAC-3’) and IMP-R
(5’-GTATGTTTCAAGAGTGATGC-3’) for the blaIMP gene under
PCR conditions, as described previously, which amplifies a
587-base pair (bp) amplicon (8). The PCR purification kit
(Bioneer Co., Korea) was used to purify the PCR products,
and sequencing of the forward strand was performed by
Bioneer Co. (Korea). The nucleotide sequences were an-
alyzed with Chromas 1.45 and MEGA-4 software, and with
BLAST on the NCBI website.
3.1. Statistical Analysis
The statistical analysis was performed with SPSS (ver-
sion 19, Chicago, IL, USA).
4. Results
The demographic data are presented in Table 1. The
mean age of the studied patients was 25.8 ± 16.4 years,
ranging from 3 to 75 years. The mean body surface area
burn (BSAB) was 35.85% ± 7.58%. Eighty-one cases out
of the total of 150 enrolled patients in this study were
males (54%). Fifty-seven (38%) isolates were considered
MDR. Ninety-three isolates (62%) were XDR, and none were
PDR. The antibiotic susceptibility of the 150 P. aeruginosa
isolates is described in Table 2. Twenty-eight resistant
phenotypes were identified, of which the predominant
resistance pattern was amikacin, ciprofloxacin, imipenem,
meropenem, aztreonam, cefepime, ceftazidime, to-
bramycin, ciprofloxacin, and piperacillin/tazobactam
(45% of isolates). Of the isolates, 144 (96%) produced MBLs,
and 107 (74.3%) of the MBL producers were positive for the
blaIMP gene. Figure 1 shows the blaIMP PCR products of P.
aeruginosa isolates from the burn patients.
5. Discussion
Pseudomonas aeruginosa remains the most frequent
Gram-negative microorganism isolated from burn
wounds, and it is complicated both to treat and to control
it, due to its prolonged environmental survival time and
its ability to develop resistance to multiple antimicrobial
agents. P. aeruginosa infections mostly occur in burn
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Table 1. Demographic Information for Patients with Burn Wound Infections in This
Study
Characteristic No. (%)
Age range, y 3 - 75
Mean age, years,± SD 25.8± 16.4
Length of stay range, d 10 - 35
Mean length of stay, days,± SD 12.8 - 7.33
Length of stay, days
< 13 81 (54.2)
14 - 20 52 (34.6)





< 25% 19 (13)
26% - 40% 104 (69)
41% 27 (8)
Abbreviaion: BSAB, body surface area burn.
Figure 1. blaIMP PCR Products of P. aeruginosa Isolates from Burn Patients
Lane 1, the positive control; lanes 2, 3 and 5, Isolates were positive for blaIMP (587-bp
amplicons); lane 4, Size standards for the 100 bp ladder.
patients with various risk factors, such as carbapenem
use, broad-spectrum antibiotic use, extended length of
hospitalization, the presence of imipenem-resistant P.
aeruginosa in the unit, and a previous history of antibi-
otic therapy, chiefly with broad-spectrum types, such as
third-generation cephalosporins and carbapenems (6).
A high rate of antibiotic resistance has been seen with
P. aeruginosa wound infections in burn patients, which
causes difficulties with empiric therapy (1, 9, 10). This
study showed high resistance rates to the most clinically
relevant antibiotics for the treatment of infections caused
by P. aeruginosa, with the exception of polymyxin B and
colistin, which may be used as the final alternatives for the
management of infections caused by this bacterium. In
this study, the high resistance rate of P. aeruginosa against
carbapenems may be the result of excessive and inappro-
priate use of these antibiotics in our hospital. β-lactams,
aminoglycosides, and quinolones are the antibiotics usu-
ally used in hospitals for the prevention and treatment
of P. aeruginosa infections, but their unreasonable use
is related to the selection and spread of strains resistant
to them. P. aeruginosa strains isolated from burn pa-
tients hospitalized in a major burn center in Tehran, Iran,
showed that 89% were resistant to ticarcillin-clavulanate,
76% to imipenem and gentamicin, and 20% to meropenem
(10). Resistance of P. aeruginosa to antibiotics is the result
of the production of enzymes that inactivate and degrade
antibiotics, reducing the membrane permeability and the
eﬄux system (11). The use of imipenem as the first choice
of treatment for MDR P. aeruginosa in this unit provides
a possible explanation for the presence of increasing
imipenem-resistant and meropenem-resistant isolates. It
is likely that piperacillin/tazobactam is the most efficient
drug because it is infrequently used. The results showed
that blaIMP was significantly correlated with aztreonam
resistance in P. aeruginosa infections. The production of
the IMP-1 enzyme, encoded by the transferable MBL gene,
blaIMP, was first isolated in P. aeruginosa in Japan (12). It is
important to note that the blaIMP gene can be transmitted
between gram-negative bacteria, so the increase of MBLs is
a risk in antimicrobial therapy with β-lactam antibiotics
and carbapenems (11). When carbapenems are used as
single agents against originally susceptible isolates of P.
aeruginosa, resistance may emerge during therapy. The
combination of tazobactam with piperacillin results in an
enhanced spectrum of activity against many, but not all,
organisms containing plasmid-mediated β-lactamases.
Aztreonam is a monocyclic β-lactam with good in vitro
activity against P. aeruginosa infections, but when used
alone, resistance may appear. MBL-producing P. aeruginosa
strains have now emerged in our burn patients. MBLs
have also been reported in other parts of Asia, Europe,
North America, South America, Australia, Japan, and Iran
(13-22). The prevalence of blaIMP genes in MBL-producing P.
aeruginosa isolates from burn wounds in Tehran has been
reported at 56.25% (23).
Carbapenem-resistant P. aeruginosa is usually resis-
tant to all β-lactams and fluoroquinolones. The intrin-
sic resistance of these organisms further limits antibi-
otic selections. Polymyxins are the basis of treatment for
Arch Trauma Res. 2016; 5(3):e33664. 3
RadanM et al.
Table 2. Frequency of Resistant Rates to Antimicrobial Agents for 150 P. aeruginosa Isolates from Burn Patientsa
Antibiotic agent Resistance Pattern
R I S
Piperacillin/tazobactam, 100/10µg 106 (70.7) 2 (1.3) 42 (28)
Aztreonam, 30µg 130 (86) 3 (2) 18 (12)
Cefepime, 30µg 139 (92.7) 0 11 (7.3)
Ceftazidime, 30µg 143 (95.3) 0 7 (4.7)
Amikacin, 30µg 144 (96) 0 6 (4)
Imipenem, 10µg 144 (96) 0 6 (4)
Meropenem, 10µg 144 (96) 0 6 (4)
Tobramycin, 10µg 145 (96.7) 0 5 (3.3)
Ciprofloxacin, 5µg 145 (96.7) 0 5 (3.3)
Colistin, 10µg 0 0 150 (100)
Polymyxin B, 300 units 0 0 150 (100)
aData are expressed as No. (%)
Abbreviaion: I, intermediate;R, resistant; S, susceptible.
carbapenem-resistant P. aeruginosa, and are usually used
in combination with other agents. Burn patients infected
with carbapenemase-producing P. aeruginosa should be
placed on contact-safety measures.
Pseudomonas aeruginosa skin infections that compli-
cate burn injuries are significant infections linked to a very
high mortality rate, in spite of antibiotic therapy. The high
rate of carbapenem-resistant P. aeruginosa in our burn pa-
tients complicates empiric antibiotic therapy. In conclu-
sion, we have shown that blaIMP-producing P. aeruginosa
isolates is a rising threat in our burn care unit, and they
should be controlled by conducting infection-control as-
sessments in parallel with the development and imple-
mentation of control measures.
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